2
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Serum tumour-associated trypsin inhibitor (TATI) and renal function

, , , , , & show all
Pages 653-656 | Received 06 Jun 1996, Accepted 10 Sep 1996, Published online: 08 Jul 2009
 

Abstract

Tumour-associated trypsin inhibitor (TATI) is a low molecular weight (MW) protein employed as a tumour marker. The blood levels of some low MW proteins increase in renal insufiiciency. The aim of this study is to evaluate the relationship between serum TATI and glomerular filtration rate (GFR). Serum β2-microglobu-lin (β2M) and plasma creatinine were also determined. The decrease of GFR was accompanied by an increase in the other parameters. The maximum increase of TATI was from a mean basal value of 8.51 ± 5.58 μg 1−1 in subjects with normal renal function to 107.27 ± 63.34 μg 1−1 in patients with renal failure; β2M increased from 1.45 ± 0.38 to 11.16 ± 5.73 mg 1−1 and creatinine from 1.05 ± 0.17 to 5.07± 1.93 mg dl−1. The increase in TATI occurs sooner and is greater than that of β2M and of creatinine. These results suggest that TATI is handled by the kidney. It is a sensitive marker of reduction in renal function. When TATI is used as a tumour marker, renal function must be taken into account in the evaluation of the results.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.